Amphastar Pharmaceuticals (AMPH) Long-Term Deferred Tax: 2013-2024
Historic Long-Term Deferred Tax for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Dec 2024 value amounting to $71.1 million.
- Amphastar Pharmaceuticals' Long-Term Deferred Tax rose 33.56% to $71.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.1 million, marking a year-over-year increase of 33.56%. This contributed to the annual value of $71.1 million for FY2024, which is 33.56% up from last year.
- As of FY2024, Amphastar Pharmaceuticals' Long-Term Deferred Tax stood at $71.1 million, which was up 33.56% from $53.3 million recorded in FY2023.
- Over the past 5 years, Amphastar Pharmaceuticals' Long-Term Deferred Tax peaked at $71.1 million during FY2024, and registered a low of $22.4 million during FY2021.
- Moreover, its 3-year median value for Long-Term Deferred Tax was $53.3 million (2023), whereas its average is $54.3 million.
- As far as peak fluctuations go, Amphastar Pharmaceuticals' Long-Term Deferred Tax fell by 10.33% in 2021, and later soared by 72.00% in 2022.
- Amphastar Pharmaceuticals' Long-Term Deferred Tax (MRY) stood at $25.0 million in 2020, then decreased by 10.33% to $22.4 million in 2021, then skyrocketed by 72.00% to $38.5 million in 2022, then soared by 38.22% to $53.3 million in 2023, then surged by 33.56% to $71.1 million in 2024.
- Its Long-Term Deferred Tax stands at $71.1 million for FY2024, versus $53.3 million for FY2023 and $38.5 million for FY2022.